首页 / 产品中心 / 单克隆抗体 /

货号: YP-rAb-17216
促销价:

产品介绍

反应种属
Human
应用范围
WB,IHC,IF,ELISA
抗体类型
单克隆抗体
基因名称(Gene Name)
UGT1A1 GNT1 UGT1
蛋白名称
UDP-glucuronosyltransferase 1A1
分子量(DA)
60kD
免疫原
特异性
Endogenous
组成
PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
来源
Monoclonal, Rabbit,IgG
稀释比例
IHC 1:200-1:1000; WB 1:500-1:2000; IF 1:200-1:1000; ELISA 1:5000-1:20000; Note: For IHC, we suggest antigen retrieval with TE buffer pH 9.0
纯化工艺
Protein A
浓度
0.5 mg/ml
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
其他名称
UGT1A1;UDP-glucuronosyltransferase 1A1;UD11;UGT1A1 GNT1 UGT1
背景
This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The preferred substrate of this enzyme is bilirubin, although it also has moderate activity with simple phenols, flavones, and C18 steroids. Mutations in this gene result in Crigler-Najjar syndromes types I and II and in Gilbert syndrome. [provided by RefSeq, Jul 2008],
功能
Alternative products:A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues,Alternative products:A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues,Catalytic activity:UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside.,Caution:The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data.,Disease:Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type I (CN-I) [MIM:218800]. CN-I patients have severe hyperbilirubinemia and usually die of kernicterus (bilirubin accumulation in the basal ganglia and brainstem nuclei) within the first year of life. CN-I inheritance is autosomal recessive.,Disease:Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type II (CN-II) [MIM:606785]. CN-II patients have less severe hyperbilirubinemia and usually survive into adulthood without neurologic damage. Phenobarbital, which induces the partially deficient glucuronyl transferase, can diminish the jaundice. CN-II inheritance is autosomal dominant.,Disease:Defects in UGT1A1 are the cause of Gilbert syndrome [MIM:143500]. Gilbert syndrome occurs as a consequence of reduced bilirubin transferase activity and is often detected in young adults with vague nonspecific complaints.,Disease:Defects in UGT1A1 may be a cause of transient familial neonatal hyperbilirubinemia [MIM:237900]. The defects is characterized by excessive concentration of bilirubin in the blood, which may lead to jaundice. Breast milk jaundice is a common problem in nursing infants. It has been ascribed to various breast milk substances, but the component or combination of components that is responsible remains unclear. Defects of UGT1A1 are an underlying cause of the prolonged unconjugated hyperbilirubinemia associated with breast milk. One or more components in the milk may trigger the jaundice in infants who have such mutations. Mutations are identical to those detected in patients with Gilbert syndrome [MIM:143500], a risk factor of neonatal non-physiologic hyperbilirubinemia and a genetic factor in fasting hyperbilirubinemia.,Disease:The Gilbert syndrome is shown to occur as a consequence of reduced bilirubin transferase activity. The disorder, is most often detected in young adults with vague nonspecific complaints. A more severe inheritable deficiency in bilirubin activity exist in Crigler-Najjar (CN): patients with type I (recessive trait) have severe hyperbilirubinemia and usually die of kernicterus (bilirubin accumulation in the basal ganglia and brainstem nuclei) within the first year of life. Patients with type II (dominant trait) have less severe hyperbilirubinemia and usually survive into adulthood without neurologic damage. Phenobarbital, which induces the partially deficient glucuronyl transferase, can diminish the jaundice.,Function:UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.,Function:UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate.,Function:UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols.,induction:By phenobarbital.,online information:Glucuronosyltransferase entry,polymorphism:Polymorphisms in the UGT1A6 gene define four common haplotypes: UGT1A6*1, UGT1A6*2, UGT1A6*3 and UGT1A6*4. Liver tissue samples that were homozygous for UGT1A6*2 exhibited a high rate of glucuronidation relative to tissues with other genotypes. Biochemical kinetic studies indicate that the UGT1A6*2 allozyme, expressed homozygously, had almost two-fold greater activity toward p-nitrophenol than UGT1A6*1 and when expressed heterozygously (UGT1A6*1/*2) it is associated with low enzyme activity. Common genetic variation in UGT1A6 confers functionally significant differences in biochemical phenotype. This genetic variation might impact clinical efficacy or toxicity of drugs metabolized by UGT1A6.,polymorphism:There are four common allelic UGT1A7 variants which exhibit significant differences in catalytic activity towards 3-, 7-, and 9-hydroxy-benzo(a)pyrene. UGT1A7*3 exhibits a 5.8-fold lower relative Vmax compared to UGT1A7*1, whereas UGT1A7*2 and UGT1A7*4 have a 2.6- and 2.8-fold lower relative Vmax than UGT1A7*1, respectively, suggesting that these mutations confer slow glucuronidation phenotype.,similarity:Belongs to the UDP-glycosyltransferase family.,subunit:Part a large chaperone multiprotein complex comprising CABP1, DNAJB11, HSP90B1, HSPA5, HYOU, PDIA2, PDIA4, PPIB, SDF2L1, UGT1A1 and very small amounts of ERP29, but not, or at very low levels, CALR nor CANX.,tissue specificity:Colon specific.,tissue specificity:Expressed in liver. Not expressed in skin or kidney.,tissue specificity:Expressed in skin, kidney and liver.,tissue specificity:Liver and colon.,tissue specificity:Liver and gastric tissue.,tissue specificity:Liver.,

展开

产品详情

客户数据及评论 (0)

折叠内容

文献引用

折叠内容

优品生物的抗体,可以回收利用几次?

首先,一般抗体不推荐客户回收利用,抗体使用之后缓冲体系已经发生改变,不同客户在回收抗体的保存条件上也会有差异,所以抗体回收使用效果无法保证。另外,优品生物也做过一批抗体回收验证测试,测试结果显示不同抗体可回收次数不同,一般效价越高的抗体,可重复使用的次数越多,客户可根据实验情况来确定。
注:我们将孵育完毕后剩余的抗体回收到离心管中置于4℃保存,效价高的抗体可至少保存1周,至少重复利用3次。

收起

优品生物作为国产抗体品牌的优势?

优品生物是国产品牌,通过聚焦抗体与酶核心技术,致力于打破国际技术的垄断,我们拥有包括兔多克隆抗体、小鼠单克隆抗体、兔单克隆抗体的生产研发平台,同时也有包括WB,IP在内的检测平台,我们对每一支自产的抗体进行了严格的检测。当然,我们部分直销地区也可以帮客户代购进口品牌的产品。同时也有抗体定制服务。优品生物l抗体优势:1,严自检,保质量;2产品多,指标全;3,价格低,货期短。

收起

优品生物抗体成分?

优品生物抗体成分在平时工作当中,常会有客户咨询我们的抗体用的什么buffer进行保存,一般来说,我们的buffer的成分是:PBS含0.03%的proclin300、0.05%牛血清白蛋白、50%甘油;也有一些是PBS含0.03%的proclin300,50%甘油。防腐剂 Proclin 300活性成分主要是2-甲基-4-异噻唑啉-3-酮(MCI)和5-氯-2-甲基-4-异噻唑啉-3-酮(CMCI)。ProClin生物灭活剂能够迅速穿透细胞膜,抑制对细胞呼吸至关重要的特定酶,因此一接触微生物有机体就会立即抑制细胞活性。ProClin的多个特定毒性位点可以防止微生物产生高水平的耐药性。

收起

实验方案

折叠内容
>